Study on Autologous Osteoblastic Cells Implantation to Early Stage Osteonecrosis of the Femoral Head

NCT01529008 | Terminated Phase 3 Results DMC

• 1 other identifier: PREOB-ON3
• Study Type: interventional
• Target: 68
• Locations: 0 countries
• Sites: N/A

Brief Summary

Non-traumatic osteonecrosis is a painful disorder of the hip characterized by a necrosis of the osteomedullary tissue, which leads to subchondral bone collapse and joint destruction. Core decompression is currently the treatment of choice for early stage osteonecrosis of the femoral head. This method consists in decompressing the rigid intra-osseous chamber to promote revascularization, thus halting progression of the disease and stimulating repair. Still this treatment remains highly controversial, since the success rates of the first studies have not been repeated. The exact pathology mechanisms involved in osteonecrosis have not yet be fully elucidated. Several hypotheses have been evoked, including fat embolism, trabecular bone microfractures, microvascular tamponade and, more recently, impaired bone and/or mesenchymal cells recruitment. Three studies have indicated the potential clinical benefits of cell-based approaches for the treatment of osteonecrosis (Hernigou 1997, Hernigou \& Beaujean 2002, Gangji et al. 2004). This is on the basis of these observations that a proprietary population of autologous osteoblastic cells (PREOB®) has been developed. This Phase 3 study aims at demonstrating the efficacy and safety of PREOB® in the treatment of early stage osteonecrosis of the femoral head. More specifically, the purpose of the study is to demonstrate that core decompression/PREOB® implantation into the necrotic lesion is superior to core decompression/placebo implantation in relieving hip symptoms and halting (or reverting) radiological progression of the disease.

Conditions

Osteonecrosis of the Femoral Head

Keywords

Osteonecrosis; Femoral Head; Hip; Orthopedics; Bone; Musculoskeletal Disorders

Outcome Measures

Primary Outcomes (1)

• Percentage of Treatment Responders

  A patient was considered as having responded to treatment if: * the WOMAC VA3.1 pain subscale score (Western Ontario and McMaster Universitie Visual Analogue scale) of the study treated hip improved from baseline by at leat the MCID (minimal clinically important difference ) the WOMAC VA3.1 pain subscale score is Visual score based on 10 cm and * the study treated hip did not progress to fractural stages (ARCO III or higher) as assessed by conventional X-ray

  24 months

Study Arms (2)

Core decompression/PREOB® implantation

EXPERIMENTAL

Drug: Core decompression/PREOB® implantation

Core decompression/placebo implantation

PLACEBO COMPARATOR

Drug: Core decompression/placebo implantation

Interventions

Core decompression/PREOB® implantation DRUG

All patients will undergo a core decompression under general anesthesia combined with the implantation of PREOB® into the necrotic lesion (single administration).

Core decompression/PREOB® implantation

Core decompression/placebo implantation DRUG

All patients will undergo a core decompression under general anesthesia combined with the implantation of placebo into the necrotic lesion (single administration).

Core decompression/placebo implantation

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Men or women between 18 and 70 years (inclusive) with a diagnosis of ARCO Stage I or II non-traumatic osteonecrosis of the femoral head, confirmed by central imaging analysis based on X-ray and MRI.
• Ability to provide a written, dated, and signed informed consent prior to any study related procedure and to understand and comply with study requirements
• Diagnosis of Osteonecrosis:
• ARCO stage I associated with WOMAC® VA3.1 pain score ≥20 mm and necrotic angle sum ≥190° based on sagittal and coronal MRI views or
• ARCO stage II associated with WOMAC® VA3.1 pain score ≥20 mm if necrotic angle sum \<190° based on sagittal and coronal MRI views or
• ARCO stage II associated or not with pain if necrotic angle sum is ≥190° based on sagittal and coronal MRI views
• Associated with corticosteroid and/or with alcohol abuse and/or idiopathic
• Normal haematology function, defined as leukocytes ≥3000/mm3, absolute neutrophils count ≥1500/mm3, platelets ≥140,000/mm3, and haemoglobin concentration ≥10g/dl (peripheral blood test)

You may not qualify if:

• Current symptoms and/or signs related to the disease under study
• Exclusively diaphyseal or metaphyseal osteonecrotic lesion
• Traumatic or hyperbaric osteonecrosis, or osteonecrosis associated with hemoglobinopathy or coagulopathy (e.g., thalassemia, sickle cell disease,…), or Gaucher's disease
• Any other focal or diffuse bone marrow lesion
• Osteoarthritis at the target hip defined as Kellgrens stage ≥2, as assessed by the Central Radiologist
• Patients suffering from any medical conditions interfering with patient's pain evaluation of the hip under evaluation, such as knee arthritis.
• Bone fracture or bone infection at hip under evaluation.
• Patients who are candidates for any predictable joint replacement on the hip that is evaluated Current or previous diagnoses, signs and/or symptoms
• Active hepatitis B (defined as positive HBs Ag and/or positive PCR), or active hepatitis C (defined as positive PCR), positive serology for HIV, or Syphilis, or HTLV-1, and any other tests that may be required by the authorities in case of a new disease outbreak that can affect the safety of the physicians and operators at the time of patient screening.
• Presence, or previous history, of risks factors for diseases caused by prions, and recipients of grafts of cornea, sclera, and dura mater
• History of blood loss exceeding 450 ml (incl. donations) within 1 month of screening
• Renal impairment defined by an estimated creatinine clearance value \< 30 ml per min, calculated with the Cockcroft-Gault formula
• Hepatic impairment, defined as alanine aminotransferase or aspartate aminotransferase ≥ 3 times the upper limit of normal
• Poorly controlled diabetes mellitus, defined as HbA1C \> 9%
• Global sepsis

Sponsors & Collaborators

• Bone Therapeutics S.A: lead

Related Publications (1)

• Jayankura M, Thomas T, Seefried L, Dubrana F, Gunther KP, Rondia J, Davis ET, Winnock de Grave P, Carron P, Gangji V, Vande Berg B, Godeaux O, Sonnet W. Does Adjunction of Autologous Osteoblastic Cells Improve the Results of Core Decompression in Early-stage Femoral Head Osteonecrosis? A Double-blind, Randomized Trial. Clin Orthop Relat Res. 2023 Aug 1;481(8):1527-1540. doi: 10.1097/CORR.0000000000002610. Epub 2023 Mar 24.

  PMID: 36961220 DERIVED

MeSH Terms

Conditions

Legg-Calve-Perthes Disease; Osteonecrosis; Musculoskeletal Diseases

Condition Hierarchy (Ancestors)

Femur Head Necrosis; Bone Diseases; Necrosis; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Results Point of Contact

• Title: Chief Medical Officer
• Organization: Bone Therapeutics

Regulatory@bonetherapeutics.com

+32 493 09 73 66

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 2, 2012
• First Posted: February 8, 2012
• Study Start: November 1, 2011
• Primary Completion: May 1, 2017
• Study Completion: November 1, 2018
• Last Updated: June 24, 2022
• Results First Posted: June 24, 2022

Record last verified: 2022-06